Regeneron Pharmaceuticals’ (REGN) “Market Perform” Rating Reaffirmed at Wells Fargo & Company

Wells Fargo & Company reaffirmed their market perform rating on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a research report released on Tuesday.

Several other research analysts also recently commented on REGN. Piper Jaffray Companies reaffirmed a hold rating and set a $447.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 20th. Leerink Swann reaffirmed a buy rating and set a $530.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, September 21st. Robert W. Baird reaffirmed a neutral rating and set a $448.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, September 23rd. Roth Capital reaffirmed a buy rating and set a $520.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, September 23rd. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a buy rating and set a $521.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 27th. Fifteen equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Regeneron Pharmaceuticals has a consensus rating of Buy and a consensus price target of $455.26.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 2.18% on Tuesday, hitting $364.85. The company had a trading volume of 1,343,156 shares. The stock’s 50-day moving average price is $379.63 and its 200 day moving average price is $387.73. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $511.31. The company has a market capitalization of $38.25 billion, a P/E ratio of 53.20 and a beta of 1.80.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, November 4th. The biopharmaceutical company reported $3.13 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.73 by $0.40. Regeneron Pharmaceuticals had a return on equity of 21.51% and a net margin of 16.52%. The company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.29 billion. During the same quarter last year, the business posted $3.47 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 7.3% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals will post $11.67 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Regeneron Pharmaceuticals’ (REGN) “Market Perform” Rating Reaffirmed at Wells Fargo & Company” was originally published by Community Financial News and is the propert of of Community Financial News. If you are reading this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this piece of content can be read at https://www.com-unik.info/2017/01/11/regeneron-pharmaceuticals-regn-market-perform-rating-reaffirmed-at-wells-fargo-company.html.

In related news, Director Charles A. Baker sold 3,000 shares of the company’s stock in a transaction dated Monday, December 12th. The shares were sold at an average price of $392.02, for a total transaction of $1,176,060.00. Following the transaction, the director now directly owns 12,000 shares in the company, valued at approximately $4,704,240. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Joseph L. Goldstein sold 2,125 shares of the company’s stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $450.00, for a total transaction of $956,250.00. Following the transaction, the director now owns 15,125 shares in the company, valued at $6,806,250. The disclosure for this sale can be found here. Corporate insiders own 10.40% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. TrueNorth Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $3,125,000. Piedmont Investment Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $6,902,000. LPL Financial LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $1,233,000. Credit Suisse AG increased its position in shares of Regeneron Pharmaceuticals by 2.5% in the third quarter. Credit Suisse AG now owns 258,909 shares of the biopharmaceutical company’s stock valued at $104,086,000 after buying an additional 6,236 shares during the last quarter. Finally, Ameritas Investment Partners Inc. increased its position in shares of Regeneron Pharmaceuticals by 8.9% in the third quarter. Ameritas Investment Partners Inc. now owns 3,661 shares of the biopharmaceutical company’s stock valued at $1,472,000 after buying an additional 298 shares during the last quarter. Institutional investors own 68.21% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

What are top analysts saying about Regeneron Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regeneron Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit